DOCSLIB.ORG

Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies1 3040 Vol. 7, 3040–3046, October 2001 Clinical Cancer Research Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies1 Olga Lyass, Ayala Hubert, and cancer patients. In four of seven responders, the time to 2 Alberto A. Gabizon disease progression exceeded 1 year. Doxil 1-h (Cmax equiv- Department of Oncology, Hadassah-Hebrew University Medical alent) levels were assessed in 20 patients. The mean Doxil Center, Jerusalem 91120, Israel Cmax (mg/l plasma) increased gradually with dose escalation ,from 14.7 ؎ 1.9 for 40 mg/m2, to 17.3 ؎ 3.0 for 50 mg/m2 2 2 ؎ and 23.3 5.5 for 60 mg/m . The 60 mg/m Cmax was similar ABSTRACT to data obtained in parallel clinical studies at our institution Purpose: Our first objective was to evaluate the feasi- with single-agent Doxil at 60 mg/m2. However, the 7-day bility of administering a combination of Doxil, a pegylated Doxil postinfusion levels were significantly lower in patients liposome formulation of doxorubicin, and cisplatin and to receiving the Doxil-cisplatin combination than in those re- determine the maximum tolerated dose of the combination. ceiving single-agent Doxil. A secondary objective was to examine Doxil peak and 7-day Conclusion: Doxil can be administered at full maximum postinjection plasma levels at the various dose levels tested. tolerated dose (50 mg/m2 every 4 weeks) in combination with Methods: Patients with advanced solid tumors were 60 mg/m2 cisplatin, with no evidence of major overlapping treated every 4 weeks with cisplatin on day 1 and Doxil on toxicities. Palmar-plantar erythrodysesthesia incidence and day 2. In the first three dose levels, the dose of Doxil was severity appears to be diminished, in comparison with data fixed at 40 mg/m2, whereas the dose of cisplatin was esca- available for single-agent Doxil. Plasma concentration data lated from 40 to 50 and 60 mg/m2. At the fourth and fifth point to an accelerated clearance of Doxil when adminis- dose levels, the dose of cisplatin was fixed at 60 mg/m2, tered after cisplatin. whereas the dose of Doxil was escalated to 50 and to 60 mg/m2. Plasma Doxil (doxorubicin-equivalent) levels were measured by a high-performance liquid chromatography INTRODUCTION assay with fluorescence detection at 1 h and 7 days after The anthracycline antibiotic doxorubicin is one of the most infusion of Doxil. widely used antineoplastic agents and the mainstay of chemo- Results: Twenty-six patients entered the study. Twenty- therapy for lymphomas and a variety of solid tumors. Unfortu- four patients completed a minimum of 2 courses and were nately, toxicity limits the therapeutic activity of doxorubicin and fully assessable for toxicity and efficacy. Eighteen patients may preclude adequate dosing. Development of doxorubicin had received prior chemotherapy, 11 of them with anthra- encapsulation in liposomes is one of the attempts to improve the cycline-containing regimens. A total of 177 courses were therapeutic index of the drug. administered within the study. In 12 patients, cisplatin was Pegylated liposomal doxorubicin (Doxil, also known as discontinued after 1 to 13 courses, and Doxil was continued Caelyx) is a novel formulation of doxorubicin in long-circulat- alone for 1–22 courses. All other patients received both ing (Stealth) liposomes that drastically changes the drug phar- drugs until discontinuation of therapy. The dose-limiting macokinetics and biodistribution (1). The formulation markedly toxicities were neutropenia and mucositis. Grade 4 neutro- lengthens liposome circulation time by retarding reticulo-endo- penia was seen in 3 patients (one with neutropenic fever) at thelial system clearance. Eventually, large numbers of lipo- dose levels 4 and 5. Grade 3 mucositis was observed in 4 somes are extravasated through the abnormally permeable ves- patients at dose levels 3, 4, and 5. In contrast, the most sels characteristic of many tumors, resulting in enhanced severe palmar-plantar erythrodysesthesia manifestation was liposome deposition in tumors (2, 3). The toxicity profile of grade 2 seen in 1 patient only. Tumor responses included Doxil is characterized by dose-limiting mucocutaneous toxici- seven partial responses, of which three were in ovarian ties, mild myelosuppression, minimal alopecia, and no apparent cardiac toxicity (4). Doxil appears to be the most active agent available for Kaposi’s sarcoma (5, 6) and has shown significant activity against a variety of solid tumors (reviewed in Ref. 7), Received 3/30/01; revised 6/8/01; accepted 7/9/01. specifically in recurrent epithelial ovarian carcinoma (8, 9) and The costs of publication of this article were defrayed in part by the metastatic breast cancer (10, 11). payment of page charges. This article must therefore be hereby marked Cisplatin is one of the most potent chemotherapeutic agents advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. available and forms the basis of many standard combination 1 Supported by ALZA Corporation. A preliminary report on this study chemotherapy regimens. Cisplatin is used in combination with was presented in poster form at the 1999 European Conference on doxorubicin in the treatment of a variety of solid tumors. These Clinical Oncology (Lyass, O., Hubert, A., Tzemach, D., et al., Eur. J. two agents have different mechanisms of action, show no cross- Cancer, 35: S287, 1999). 2 To whom requests for reprints should be addressed, at Department of resistance, and their toxicities do not overlap. Because Doxil Oncology, Hadassah Medical Center, Kiryat Hadassah, Jerusalem appears to be a promising form of delivering doxorubicin with 91120, Israel. Fax: 972-2-643-0622; E-mail: [email protected]. decrease of some of the most problematic toxicities (cardiac Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2001 American Association for Cancer Research. Clinical Cancer Research 3041 Table 1 Dose levels clide ventriculography (MUGA scan) or echocardiography. No. of Cisplatin, Doxil, Prior treatment with anthracyclines was allowed only if the 2 Dose level patients mg/m2, day 1a mg/m2, day 2a cumulative dose of doxorubicin was Ͻ400 mg/m . The study 1 5 40 40 was approved by the Hadassah institutional review board, and 2 4 50 40 patients were required to provide signed, witnessed informed 3 4 60 40 consent. 4 5 60 50 Pretreatment evaluation included a complete history and 5 8 60 60 physical examination and documentation of performance status. a Cycles every 4 weeks. Laboratory evaluation included a complete blood count, chem- istry panel with liver and renal function tests, prothrombin time, and serum tumor marker levels if relevant to tumor condition. toxicity and myelosuppression), a combination with cisplatin is All patients had a pretreatment 12-lead electrocardiogram and likely to be tolerated without enhanced toxicity, which may cardiac ejection fraction evaluation. Radiographic evaluation enable us to deliver to patients optimal doses of both agents and included a chest radiograph and any other imaging examinations achieve significant advantages over standard cisplatin-doxoru- (computed tomography scan and ultrasonography) indicated by bicin combination. the type and site of the malignancy. Before each new treatment The principal objectives of the present study were to eval- cycle, vital signs, weight, symptom-oriented physical check, uate the feasibility of administering a combination of Doxil and Karnofsky status assessment, complete blood count, chemistry cisplatin and to determine the MTD3 of the combination. In panel with liver and renal function tests, and report on adverse addition, Doxil plasma levels were assessed in subgroup of events occurring after the previous dose were obtained. During patients and compared with our records for patients receiving the first cycle, a complete blood count was repeated on a weekly Doxil as single agent (11, 12). basis. From the second cycle and onward, a complete blood count was performed before treatment and 2 weeks after each 2 PATIENTS AND METHODS dose. After a 300 mg/m cumulative dose of Doxil, cardiac ejection fraction was reevaluated by MUGA scan or echocar- Study Design. The study reported herein was a single- diography. institution Phase I trial at the Hadassah Medical Center. Be- Treatment was administered until disease progression or tween February 1997 and October 1998, 26 patients were en- dose-limiting toxicity. All patients who received one or more rolled. courses of cisplatin and Doxil were evaluable for toxicity. The starting dose of Doxil was 40 mg/m2 combined with Toxicity was graded according to the National Cancer Institute 40 mg/m2 cisplatin every 4 weeks. Doses of Doxil and cisplatin Common Toxicity Criteria. For the sake of clarity, PPE grades were escalated according to a planned sequence (Table 1), 3–4 always entailed a situation in which simple physical activ- covering a range of 40–60 mg/m2 for both drugs. A minimum ities (writing, clenching fists, and walking with closed shoes) of 4 patients receiving at least 2 courses of treatment were were highly painful or unfeasible. enrolled per dose level. At each dose level, the study progressed For stomatitis and PPE, dose-limiting toxicity was defined to the next level if no patient experienced nonhematological as any grade 3 or 4. For patients with grade 3 or 4 toxicity, the toxicity of grade 3 or hematological toxicity of grade 4 during dose of subsequent courses was reduced by 25%. Patients were the two first dosing cycles. If only one patient experienced grade retreated only after the toxicity grade returned to 0 to 1. If 3 or 4 toxicity, up to 4 subsequent patients were to be accrued necessary, the dosing intervals could be increased by 1 or 2 at the same dose level until the dose tolerance could be accu- weeks to enable resolution of toxicity. rately assessed. If two or more patients experienced grade 3 or For myelosuppression, dose-limiting toxicity was defined 4 toxicity per dose level, then this level was declared as the as grade 4.
Load more

Recommended publications
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • Arsenic Trioxide Is Highly Cytotoxic to Small Cell Lung Carcinoma Cells
    160 Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells 1 1 Helen M. Pettersson, Alexander Pietras, effect of As2O3 on SCLC growth, as suggested by an Matilda Munksgaard Persson,1 Jenny Karlsson,1 increase in neuroendocrine markers in cultured cells. [Mol Leif Johansson,2 Maria C. Shoshan,3 Cancer Ther 2009;8(1):160–70] and Sven Pa˚hlman1 1Center for Molecular Pathology, CREATE Health and 2Division of Introduction Pathology, Department of Laboratory Medicine, Lund University, 3 Lung cancer is the most frequent cause of cancer deaths University Hospital MAS, Malmo¨, Sweden; and Department of f Oncology-Pathology, Cancer Center Karolinska, Karolinska worldwide and results in 1 million deaths each year (1). Institute and Hospital, Stockholm, Sweden Despite novel treatment strategies, the 5-year survival rate of lung cancer patients is only f15%. Small cell lung carcinoma (SCLC) accounts for 15% to 20% of all lung Abstract cancers diagnosed and is a very aggressive malignancy Small cell lung carcinoma (SCLC) is an extremely with early metastatic spread (2). Despite an initially high aggressive form of cancer and current treatment protocols rate of response to chemotherapy, which currently com- are insufficient. SCLC have neuroendocrine characteristics bines a platinum-based drug with another cytotoxic drug and show phenotypical similarities to the childhood tumor (3, 4), relapses occur in the absolute majority of SCLC neuroblastoma. As multidrug-resistant neuroblastoma patients. At relapse, the efficacy of further chemotherapy is cells are highly sensitive to arsenic trioxide (As2O3) poor and the need for alternative treatments is obvious. in vitro and in vivo, we here studied the cytotoxic effects Arsenic-containing compounds have been used in tradi- of As2O3 on SCLC cells.
    [Show full text]
  • Combination of Oxoplatin with Other FDA-Approved Oncology Drugs
    International Journal of Molecular Sciences Article Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs José Pedro Cerón-Carrasco Reconocimiento y Encapsulación Molecular, Universidad Católica San Antonio de Murcia Campus los Jerónimos, 30107 Murcia, Spain; [email protected] Received: 16 April 2020; Accepted: 2 July 2020; Published: 3 July 2020 Abstract: Although Pt(II)-based drugs are widely used to treat cancer, very few molecules have been approved for routine use in chemotherapy due to their side-effects on healthy tissues. A new approach to reducing the toxicity of these drugs is generating a prodrug by increasing the oxidation state of the metallic center to Pt(IV), a less reactive form that is only activated once it enters a cell. We used theoretical tools to combine the parent Pt(IV) prodrug, oxoplatin, with the most recent FDA-approved anti-cancer drug set published by the National Institute of Health (NIH). The only prerequisite imposed for the latter was the presence of one carboxylic group in the structure, a chemical feature that ensures a link to the coordination sphere via a simple esterification procedure. Our calculations led to a series of bifunctional prodrugs ranked according to their relative stabilities and activation profiles. Of all the designed molecules, the combination of oxoplatin with aminolevulinic acid as the bioactive ligand emerged as the most promising strategy by which to design enhanced dual-potency oncology drugs. Keywords: cancer; drug design; organometallics; platinum-based drugs; bifunctional compounds; theoretical tools 1. Introduction The unexpected discovery of the bioactivity of Pt salts by Rosenberg about 60 years ago opened the door to a new type of cancer treatment: chemotherapy with transition metals [1].
    [Show full text]
  • Small Cell Lung Cancer (SCLC) Algorithm
    Small Cell Lung Cancer (SCLC) Page 1 of 8 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Note: Consider Clinical Trials as treatment options for eligible patients. INITIAL EVALUATION STAGE ● Pathology consistent with SCLC Limited Stage ● History and physical AJCC Stage I-III2, see Page 2 ● Laboratory studies to include hematological and full chemistry panels ● FDG PET/CT and CT chest with IV contrast ○ If FDG PET/CT not available: nuclear medicine bone scan and CT chest, abdomen, and pelvis with IV contrast ● MRI brain with IV contrast (preferred) or CT head with IV contrast ● MRI spine, lumbar puncture and bone marrow aspirate/biopsy as indicated ● Pulmonary function tests 1 Extensive Stage ● Lifestyle risk assessment AJCC Stage IV3, see Page 3 ● Molecular profiling (for never smokers) AJCC = American Joint Committee on Cancer 1 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice 2 Limited stage: Stage I-III (T any, N any, M0) per AJCC 8th edition or disease confined to the ipsilateral hemithorax
    [Show full text]
  • Cisplatin and Etoposide (Lung)
    Cisplatin and Etoposide (lung) _____________________________________________________________________________________________ Indication First line chemotherapy for patients with small cell lung cancer (SCLC), who have a good performance status (WHO PS 0-2). Concomitant radiotherapy may start with cycle 2. ICD-10 codes Codes pre-fixed with C34 Regimen details Day Drug Dose Route 1 Cisplatin 75-80mg/m² IV infusion 1 Etoposide 100mg/m² IV infusion 2 and 3 or Etoposide 100mg/m² IV infusion 2 and 3 Etoposide 200mg/m2 PO Cycle frequency 21 days Number of cycles 4 - 6 cycles (usually 4) Administration Cisplatin is administered in 500mL sodium chloride 0.9% over 60 minutes following the pre and post hydration protocol below. Infusion Fluid & Additives Volume Infusion Time Sodium Chloride 0.9% 1000mL 1 hour Mannitol 20% 200mL 30 minutes OR Mannitol 10% 400mL 30 minutes Ensure urine output > 100mL / hour prior to giving cisplatin. Give a single dose of furosemide 20mg iv if necessary. Cisplatin 500mL 1 hour Sodium Chloride 0.9% + 2g MgSO4 + 1000mL 2 hours 20mmol KCl TOTAL 2700mL or 2900mL 4 hours 30 minutes Note: Patients with magnesium or potassium below the normal range should have 2g MgSO4 and 20mmol KCl added to the pre-hydration bag and the duration of the infusion increased to 2 hours. All patients must be advised to drink at least 2 litres of fluid over the following 24 hours. IV etoposide is administered in 1000mL sodium chloride 0.9% and infused over a minimum of 1 hour. Version 1 Review date June 2018 Page 1 of 4 Oral etoposide is available as 50mg and 100mg capsules.
    [Show full text]
  • Combination Chemotherapy with Estramustine Phosphate, Ifosfamide and Cisplatin for Hormone-Refractory Prostate Cancer
    Acta Med. Okayama, 2006 Vol. 60, No. 1, pp. 43ﾝ49 CopyrightⒸ 2006 by Okayama University Medical School. Original Article http ://www.lib.okayama-u.ac.jp/www/acta/ Combination Chemotherapy with Estramustine Phosphate, Ifosfamide and Cisplatin for Hormone-refractory Prostate Cancer Haruki Kakua, Takashi Saikaa＊, Tomoyasu Tsushimab, Atsushi Nagaia, Teruhiko Yokoyamaa, Fernando Abarzuaa, Shin Ebaraa, Daisuke Manabea, Yasutomo Nasua, and Hiromi Kumona aDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700ﾝ8558, Japan, and bDepartment of Urology, Medival center of Okayama, Okayama 701-1192, Japan We evaluated the effi ciency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and cis- platin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory prostate cancer (HRPC), for which there is currently no eff ective treatment. Patients received a daily dose of 560 mg ECT in combination with 1.2 g/m2 IFM on days 1 to 5 and 70 mg/m2 CDDP on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of more than 50ｵ reduc- tion in prostate-specifi c antigen was observed in 9 of 18 patients (50ｵ), and a more than 50ｵ reduc- tion in bi-dimensionally measurable soft-tissue lesions was observed in 2 of 7 patients (29ｵ). The median duration of response among the cases showing partial response was 40 weeks, while the median duration of response of overall partial-response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable. In conclusion, the ECT, IFM and CDDP combination chemotherapy regimen is a viable treatment option for HRPC.
    [Show full text]
  • Utilization of Arsenic Trioxide As a Treatment of Cisplatin-Resistant Non-Small Cell Lung Cancer PC-9/CDDP and PC-14/CDDP Cells
    ONCOLOGY LETTERS 10: 805-809, 2015 Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells TOSHIHIRO SUZUKI1, KENICHI ISHIBASHI1, ATSUSHI YUMOTO1, KAZUTO NISHIO2 and YUKI OGASAWARA1 1Department of Analytical Biochemistry, Meiji Pharmaceutical University, Kiyose, Tokyo 204‑8588; 2Department of Genome Biology, Kinki University School of Medicine, Osaka-sayama, Osaka 589-8511, Japan Received August 26, 2014; Accepted May 20, 2015 DOI: 10.3892/ol.2015.3352 Abstract. Cisplatin is a commonly used drug in combination treatment of various cancers, including lung cancer. Cisplatin chemotherapy. However, various malignant tumors frequently is a commonly used drug for combination chemotherapy (1). acquire resistance to cisplatin. Arsenic trioxide (ATO) has Although cisplatin is a potent anticancer drug, various been approved as a chemotherapeutic drug for the treatment malignant tumors frequently acquire resistance to cisplatin, of acute promyelocytic leukemia, and the combination of limiting the clinical application of this agent (2,3). ATO and cisplatin has been revealed to demonstrate syner- Arsenite is a toxic metalloid that is widely distributed in gistic effects in ovarian and small cell lung cancer cells. Thus, the environment (4). Despite the toxicity, arsenic-containing it was hypothesized that ATO may also be active against compounds have been used in traditional Chinese medicine cisplatin-resistant non-small cell lung cancer (NSCLC) for >2,000 years (5). In addition, arsenic trioxide (ATO) has PC-9/CDDP and PC-14/CDDP cells. The present study been approved in numerous countries for the treatment of also evaluated the effects of ATO on the cisplatin-sensitive acute promyelocytic leukemia (APL) (6).
    [Show full text]
  • Enhancement of the Activity of Phenoxodiol by Cisplatin in Prostate Cancer Cells
    British Journal of Cancer (2009) 100, 649 – 655 & 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00 www.bjcancer.com Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells 1 1,2 *,1,2 RAC McPherson , PT Galettis and PL de Souza 1 2 Cancer Pharmacology and Therapeutics Laboratory, Department of Medical Oncology, St George Hospital, Sydney, New South Wales, Australia; Faculty of Medicine, University of NSW, Sydney, New South Wales, Australia Phenoxodiol is a novel isoflav-3-ene, currently undergoing clinical trials, that has a broad in vitro activity against a number of human cancer cell lines. Phenoxodiol alone inhibited DU145 and PC3 in a dose- and time-dependent manner with IC50 values of 8±1 and 38±9 mM, respectively. The combination of phenoxodiol and cisplatin was synergistic in DU145, and additive in PC3, as assessed by the Chou–Talalay method. Carboplatin was also synergistic in combination with phenoxodiol in DU145 cells. The activity of the phenoxodiol and cisplatin combination was confirmed in vivo using a DU145 xenograft model in nude mice. Pharmacokinetic data from these mice suggest that the mechanism of synergy may occur through a pharmacodynamic mechanism. An intracellular cisplatin accumulation assay showed a 35% (Po0.05) increase in the uptake of cisplatin when it was combined in a ratio of 1 mM:5mM phenoxodiol, resulting in a 300% (P 0.05) increase in DNA adducts. Taken together, our results suggest that phenoxodiol has o interesting properties that make combination therapy with cisplatin or carboplatin appealing. British Journal of Cancer (2009) 100, 649–655.
    [Show full text]
  • A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer
    284 Vol. 11, 284–289, January 1, 2005 Clinical Cancer Research A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer William K. Oh,1 Elizabeth Hagmann,1 docetaxel is 43 mg/m2 combined with estramustine and Judith Manola,2 Daniel J. George,1 carboplatin. PSA declines were seen at every dose level. Timothy D. Gilligan,1 Joseph O. Jacobson,4 Matthew R. Smith,3 Donald S. Kaufman,3 and INTRODUCTION Philip W. Kantoff 1 Prostate cancer remains the second leading cause of cancer 1Lank Center for Genitourinary Oncology, Department of Medical death in men in the United States (1). Although initially Oncology and 2Department of Biostatistical Science, Dana-Farber responsive to androgen deprivation therapy, prostate cancer Cancer Institute; 3Department of Medical Oncology, Massachusetts almost always becomes refractory to hormonal manipulation (2) 4 General Hospital Cancer Center, Boston, Massachusetts; and North Mitoxantrone chemotherapy combined with corticosteroids Shore Cancer Center, Peabody, Massachusetts provides palliative benefit in the management of symptomatic disease, but no improvement in survival (3, 4). Phase I and II ABSTRACT trials have shown that the combination of docetaxel and Purpose: To define the maximal tolerated dose, safety, estramustine is effective and well tolerated in patients with and efficacy of docetaxel, carboplatin, and estramustine in hormone refractory prostate cancer (HRPC; refs. 5–9). Two patients with hormone-refractory prostate cancer (HRPC). recently reported large phase III trials showed that docetaxel Methods: Patients with HRPC received docetaxel for 3 combined with either prednisone or estramustine was associated weeks, followed by a rest week.
    [Show full text]
  • Head and Neck Cancer
    Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN-FLUOROURACIL Regimen • Head and Neck Cancer – Cisplatin-Fluorouracil Indication • Neoadjuvant and palliative treatment of squamous cell carcinoma of the head and neck Toxicity Drug Adverse Effect Cisplatin Neuropathy, nephrotoxicity, ototoxicity Fluorouracil Diarrhoea, stomatitis The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Drugs • FBC, LFTs and U&Es prior to each cycle • Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with fluorouracil. All patients should be tested for DPD deficiency before initiation (cycle 1) to minimise the risk of these reactions Dose Modifications The dose modifications listed are for haematological, liver and renal function and drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances. Version 1.1 (November 2020) Page 1 of 6 Head and Neck – Cisplatin-Fluorouracil Haematological Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL. Criteria Eligible Level Neutrophils 1.5x10 9/L or greater Platelets 100x10 9/L or greater Defer treatment for 7 days if the neutrophil count is less than 1.5x10 9/L and / or the platelet count is less than 100x10 9/L.
    [Show full text]
  • Multiple Myeloma
    MULTIPLE MYELOMA ARSENIC TRIOXIDE Arsenic trioxide 0.25 mg/kg/day IV* Monday - Friday of Weeks 1 and 2** *Administer over 1 hour; **Administer Monday - Friday (5 days per week) during the first 2 weeks of each 4 week cycle. Repeat cycles every 28 days. NOTE: Ensure that serum electrolytes are assessed and corrected, particularly potassium and magnesium, prior to start of treatment, and maintain these values throughout the cycle. Avoid medication known to prolong the QTc interval. Obtain a 12-lead ECG prior to the first dose and ensure that the QTc interval is not greater than 460 msec. Reference: Hussein MA, et al. Br J Haematol 2004;125:470 - 6. BORTEZOMIB Bortezomib 1.3 mg/m2 IVB Days 1, 4, 8 and 11 Repeat cycle every 21 days to a maximum of 8 cycles. NOTE: Patients with progressive disease after 2 cycles or stable diseases after 4 cycles were able to receive dexamethasone 20 mg on the day of and the day after bortezomib. Reference: Richardson PG, et al. N Engl J Med 2003;348:2609 – 17. BORTEZOMIB – DOXORUBICIN - DEXAMETHASONE Bortezomib 1.3 mg/m2 IVB Days 1, 4, 8 and 11 Dexamethasone 40 mg /day PO See below (cycle dependent) Doxorubicin 9 mg/m2/day IV Days 1 - 4 Repeat cycle every 21 days for 4 cycles. NOTE: Dexamethasone dosing: 40 mg PO/day was administered on days 1 – 4, 8 – 11, and 15 – 18 of cycle 1 and on days 1 – 4 of cycles 2 – 4. Concurrent bisphosphonate therapy, gastric protection, erythropoietin and Pneumocystis carinii prophylaxis were given.
    [Show full text]
  • Radiation Treatment and Cisplatin Chemotherapy
    Form: D-8597 Your guide to: Radiation Treatment and Cisplatin Chemotherapy For people who have gynecologic cancer Read this resource to learn: • Important safety information • What you need to know about your treatment • What you need to know before your treatment starts • Where to go for your appointments • How to prepare for radiation treatment • How to prepare for chemotherapy • What are the side effects from radiation treatment and chemotherapy • What you can do to manage the side effects from radiation treatment and chemotherapy • Your treatment schedule • Who to contact if you have questions For questions about your radiation treatment appointments, call: 416 946 4501 ext. 2172 For questions about your chemotherapy appointments, call: 416 946 2220 then press 1 Your first day of treatment is: Important safety information For the next few weeks you will be getting concurrent treatment. This means you will get two therapies at the same time: • Radiation treatment • Chemotherapy These two therapies work together to help you get the best from your treatment. It is important that you get both your radiation treatments and your chemotherapy. Both treatments are needed for you to get the best outcome. Your radiation treatment and chemotherapy are two different appointments. Your radiation treatment will be organized with your radiation oncologist (radiation cancer doctor). Your chemotherapy will be organized with your gynecology oncologist (chemotherapy cancer doctor). Know who to contact about your appointments. Know what you can do to be sure you do not miss a treatment. Follow the treatment schedule at the end of this resource to help you stay safe and get the treatment you need.
    [Show full text]